Investment
Features
FeesSafety
Academy
More
Pluang+

USDT balances at major exchanges drop $4.6B as rivals USDC and RLUSD gain ground.

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
USDT balances at major exchanges drop $4.6B as rivals USDC and RLUSD gain ground.

From early July to October 1, Tether USD (USDT) balances at 19 major exchanges and lenders fell by $4.6 billion, while rival stablecoins like USD Coin (USDC) and Ripple USD (RLUSD) increased by about $1.9 billion. This shift reflects growing competition for trading deposits, although USDT remains dominant, holding roughly two-thirds of stablecoin deposits at these exchanges and 84% of stablecoin payment value year-to-date. The decline in USDT at exchanges does not fully reflect its circulating supply, as some tokens moved to wallets outside the selected firms. Incentives like Bybit's rewards for RLUSD holders contributed to the rival stablecoins' growth. Despite these changes, USDT's overall market position remains strong, especially in payments where its usage rose 45% year-over-year.

Tether USD (USDT) balances dropped by $4.6 billion at 19 exchanges and lenders from early July to October 1. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 20, 2026 06:02 WIB: out of 50 major cryptocurrencies, 42 rose and 7 fell today. Notable movers include CRV with a price of Rp6.647 and a 1-day change of +7.85%, DOT at Rp20.661 up 4.90%, and ATOM at Rp31.388 up 4.80%.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
48 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
48 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App